Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

Core Insights - Tyra Biosciences, Inc. announced the acceptance of two abstracts for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium, highlighting its focus on FGFR biology and precision medicine development [1][4] Group 1: Company Overview - Tyra Biosciences is a clinical-stage biotechnology company specializing in next-generation precision medicines targeting FGFR biology [4] - The company utilizes an in-house precision medicine platform called SNÅP for rapid drug design and predicting genetic alterations that may cause resistance to existing therapies [4] - Tyra has a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions [4] Group 2: Clinical Programs - TYRA-200 is an oral FGFR1/2/3 inhibitor currently in a Phase 1 clinical study (SURF201) for advanced intrahepatic cholangiocarcinoma and other solid tumors with FGFR2 gene alterations [2][4] - TYRA-430 is an oral FGFR4/3-biased inhibitor, with FDA clearance for a Phase 1 study in advanced hepatocellular carcinoma and other solid tumors driven by the FGF19/FGFR pathway [3][4] - The SURF201 study for TYRA-200 is designed to evaluate the maximum tolerated dose and preliminary antitumor activity, currently enrolling patients [2]